Angiotensin Converting Enzyme 2 News and Research

RSS

Study reveals Omicron sub-lineages BA.4 and BA.5 escape neutralizing antibodies elicited in response to BA.1 infection

Researchers evaluated whether neutralizing immunity elicited against Omicron sub-variant BA.1 in unvaccinated and vaccinated individuals adequately protected against infection by Omicron sub-variants, BA.4 and BA.5.

3 May 2022

Infectivity of SARS-CoV-2 Omicron variant in the intestinal tract

Researchers assessed the infectivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant in the intestinal tract.

3 May 2022

Features of SARS-CoV-2 Omicron BA.2 sublineage spike protein

Researchers assessed the traits of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 sublineage spike (S) protein.

3 May 2022

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

A new study published in the journal Gastroenterology used upper and lower gastrointestinal endoscopy to assess whether gut antigen persistence leads to post-acute COVID-19 in patients with or without post-acute COVID-19 symptoms.

3 May 2022

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

Researchers evaluated the importance of the P681 residue within the furin cleavage site of SARS-CoV-2 spike protein in determining the fusogenicity and syncytia formation ability of SARS-CoV-2 strains.

2 May 2022

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

A recent research paper posted to the bioRxiv* preprint server demonstrated that a cocktail of two synergetic antibodies extensively neutralized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including Omicron BA.1 and BA.2.

1 May 2022

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

In a new study, researchers described their self-designed chimeric receptor-binding domain-dimer vaccine approach to adapt SARS-CoV-2 variants of concern and variants of interest.

29 Apr 2022

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Researchers examined the efficiency of the main protease (Mpro) inhibitor against SARS-CoV-2.

29 Apr 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022

Study finds curcumin is a potential therapeutic agent against the Omicron variant of SARS-CoV-2

A recent study demonstrated that the phytochemical curcumin is a potent therapeutic prospect against the SARS-CoV-2 Omicron variant

29 Apr 2022

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

A new paper describes a novel method, using a specific molecule to engage T cell receptors and the virus receptor, the angiotensin-converting enzyme 2, at the same time.

28 Apr 2022

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Researchers identified a human monoclonal antibody (mAb), 87G7, with in vitro neutralizing activity against several SARS-CoV-2 VOCs, including Alpha, Beta, Gamma, Delta, and Omicron.

28 Apr 2022

Green tea catechin as pan-coronavirus attachment inhibitor

In a recent study posted to the Research Square* preprint server, researchers assessed the impact of green tea catechin epigallocatechin gallate (EGCG) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Apr 2022

Evidence of accelerated epigenetic age in SARS-CoV-2-positive patients

Researchers assessed the epigenetic aging in COVID-19 patients and its impact on COVID-19 severity by a genome-wide deoxyribonucleic acid methylation profiling analysis.

27 Apr 2022

Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern

The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.

27 Apr 2022

The preclinical potential of a herb used in traditional Chinese medicine for the treatment of COVID-19

In a study published in Cells, researchers have been investigating the effects of this extract for use against COVID-19.

27 Apr 2022

Superior T-cell immunity in COVID vaccinated

A recent study published in the journal Public Library of Science (PLOS) ONE presented the T cell and humoral immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection against the SARS-CoV-2 original and mutant strains.

27 Apr 2022

Antibodies against the original strain of SARS-CoV-2 may not work as well with omicron

If you're wondering why after two vaccination doses and a booster shot, you still got sick from the omicron strain of the virus that causes COVID-19, one possible answer may have been found in a recent study by researchers at Johns Hopkins Medicine and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

26 Apr 2022

Free fatty acid-binding pocket found to be preserved across spike proteins of beta coronaviruses

Researchers assessed the binding pocket of linoleic acid, an essential free-fatty acid in the receptor-binding domains of the spike protein of beta-coronaviruses.

26 Apr 2022

Nanobody effectively neutralizes pseudotyped ancestral SARS-CoV-2 and Omicron spike proteins

Researchers identified a nanobody inhibiting SARS-CoV-2 variants.

26 Apr 2022

Angiotensin Converting Enzyme 2 News and Research

Study reveals Omicron sub-lineages BA.4 and BA.5 escape neutralizing antibodies elicited in response to BA.1 infection

Infectivity of SARS-CoV-2 Omicron variant in the intestinal tract

Features of SARS-CoV-2 Omicron BA.2 sublineage spike protein

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

Antibody cocktail shows synergetic effects against SARS-CoV-2 Omicron in vitro and in vivo

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

Study reports an orally available SARS-CoV-2 Mpro inhibitor with potent in vivo antiviral activity

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

Study finds curcumin is a potential therapeutic agent against the Omicron variant of SARS-CoV-2

Therapeutic promise of CAR-T cell bispecific engagers against SARS-CoV-2

Identification of a SARS-CoV-2 neutralizing human monoclonal antibody with a remarkable broad-spectrum neutralization and protection efficacy

Green tea catechin as pan-coronavirus attachment inhibitor

Evidence of accelerated epigenetic age in SARS-CoV-2-positive patients

Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern

The preclinical potential of a herb used in traditional Chinese medicine for the treatment of COVID-19

Superior T-cell immunity in COVID vaccinated

Antibodies against the original strain of SARS-CoV-2 may not work as well with omicron

Free fatty acid-binding pocket found to be preserved across spike proteins of beta coronaviruses

Nanobody effectively neutralizes pseudotyped ancestral SARS-CoV-2 and Omicron spike proteins

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News